Literature DB >> 25984174

Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations.

Akihiro Katayama1, Jun Wada1, Hitomi Usui Kataoka2, Hiroko Yamasaki1, Sanae Teshigawara1, Takahiro Terami1, Kentaro Inoue1, Motoko Kanzaki1, Kazutoshi Murakami1, Atsuko Nakatsuka1, Hitoshi Sugiyama1, Norio Koide3, Hideaki Bujo4, Hirofumi Makino1.   

Abstract

Familial lecithin:cholesterol acyltransferase deficiency (FLD) is an autosomal recessive disorder characterized by corneal opacity, hemolytic anemia, low high-density lipoprotein cholesterol (HDL-C) and proteinuria. Two novel lecithin:cholesterol acyltransferase (LCAT) mutations[c.278 C>T (p.Pro69Leu); c.950 T>C (p.Met293Thr)] were identified in a 27-year-old man and in a 30-year-old woman, respectively. Both patients manifested corneal opacity, hemolytic anemia, low low-density lipoprotein cholesterol and HDL-C and proteinuria. Lipid deposits with vacuolar lucent appearance in glomerular basement membranes were observed in both cases. APOE genotype was also investigated: the first case results ϵ4/ϵ3, the second ϵ2/ϵ2; however, they shared a similar phenotype characterized by the presence of intermediate-density lipoproteins (IDL) remnant and the absence of lipoprotein-X. In conclusion, our findings suggest that APOE ϵ2/ϵ2 may not be the major determinant gene for the appearance of IDL in FLD patients.

Entities:  

Keywords:  APOE genotype; IDL remnant; familial LCAT deficiency (FLD); lipoprotein-X

Year:  2011        PMID: 25984174      PMCID: PMC4421733          DOI: 10.1093/ndtplus/sfr091

Source DB:  PubMed          Journal:  NDT Plus        ISSN: 1753-0784


Background

Mutations in the lecithin:cholesterol acyltransferase (LCAT) gene cause either familial lecithin:cholesterol acyltransferase deficiency (FLD) (OMIM# 245900) or fish-eye disease (FED, OMIM# 136120) [1]. FLD patients are characterized by a significant reduction in serum high-density lipoprotein cholesterol (HDL-C) level, corneal opacity, normochromic anemia and proteinuria with progression to end-stage renal disease [1, 2]. Plasma low-density lipoprotein cholesterol (LDL-C) levels are widely variable among FLD patients although plasma LCAT activity catalyzing HDL (LCATα activity) and catalyzing apolipoprotein B containing lipoproteins (LCATβ activity) is absent or nearly absent. The loss of LCAT activity leads to increased levels of phosphatidylcholine and free cholesterol (FC) in the blood and to the formation of an abnormal lipoprotein called lipoprotein-X (Lp-X). As a result, accumulation of FC occurs in various tissues, including the cornea, erythrocyte membrane and the kidney [3]. Recent report suggests an etiological role for Lp-X in the development of glomerulosclerosis [4]. Here, we describe two novel mutations of LCAT gene, a C to T transition in Exon 2 converting proline 69 to leucine (Pro69Leu) and a T to C transition in Exon 6 converting methionine 293 to threonine (Met293Thr). Since Baass et al. [5] hypothesized that the presence of the APOE ε2 allele contributed to the accumulation of intermediate-density lipoprotein (IDL) in the patients with LCAT deficiency, we investigated their APOE genotypes and phenotypic manifestations of the patients with FLD.

Case reports

Case presentation

Case 1.

A 27-year-old Japanese man was referred to Okayama University Hospital because he had extremely low HDL-C and LDL-C concentrations. On physical examination, he showed bilateral corneal opacity, but no other abnormal findings. Laboratory findings demonstrated a mild degree of normochoromic-normocytotic anemia (11.3 g/dL). Although his renal function was normal, (+1) proteinuria was revealed via the dipstick method (0.21 g/day). The consanguinity was found in his parents as shown in Figure 1A.
Fig. 1.

Presented cases with FLD. (A, B) Family trees of Cases 1 and 2. Squares are male, circles are female. Filled symbols indicate homozygous carriers and left filled symbols indicate heterozygous carriers. The deceased subjects are indicated with the oblique lines. Members without genetic analysis are presented in gray tone. The consanguinity of patients' parents are indicated by doubled line. (C, D) Determination of the LCAT gene sequences of proband and their families. Heterozygous mutation of mother and elder sister and homozygous mutation of proband are shown in Cases 1 (C) and 2 (D). (E, F) Renal biopsy findings of Cases 1 and 2. Electron micrograph shows lipid deposits with a vacuolar lucent appearance in the GBM (bar = 2 μm). (G–I) High-performance liquid chromatography patterns of Cases 1 (G), 2 (H) and normal healthy control (I).

Presented cases with FLD. (A, B) Family trees of Cases 1 and 2. Squares are male, circles are female. Filled symbols indicate homozygous carriers and left filled symbols indicate heterozygous carriers. The deceased subjects are indicated with the oblique lines. Members without genetic analysis are presented in gray tone. The consanguinity of patients' parents are indicated by doubled line. (C, D) Determination of the LCAT gene sequences of proband and their families. Heterozygous mutation of mother and elder sister and homozygous mutation of proband are shown in Cases 1 (C) and 2 (D). (E, F) Renal biopsy findings of Cases 1 and 2. Electron micrograph shows lipid deposits with a vacuolar lucent appearance in the GBM (bar = 2 μm). (G–I) High-performance liquid chromatography patterns of Cases 1 (G), 2 (H) and normal healthy control (I).

Case 2.

A 30-year-old Japanese woman was referred because of very low HDL-C and LDL-C associated with (1+) proteinuria via dipstick (0.08 g/day). She also showed bilateral corneal opacity and mild hemolytic anemia (11.2 g/dL), demonstrating target cells on her peripheral blood smear. Her renal function was within normal range. She was a daughter of consanguineous parents (Figure 1B).

Sequencing of LCAT gene, renal biopsy findings and LCAT activity

Direct sequencing of LCAT gene and comparison with reference sequence (NM_000229) revealed that Case 1 had a C to T nucleotide substitution in Exon 2 resulting in Pro69Leu [c.278 C>T (p.Pro69Leu)] (Figure 1C) and Case 2 had a T to C substitution in Exon 6 resulting in Met293Thr mutations [c.950 T>C (p.Met293Thr)] (Figure 1D). Both cases showed homozygous mutation and their parents showed heterozygous mutation. We further examined the APOE genotype of the presented cases. Case 1 carried APOE ε4/ε3 genotype, whereas Case 2 carried APOE ε2/ε2 genotype (Table 1). The mother of Case 1 carried APOE ε3/ε3 genotype and genomic DNAs were not available from the deceased father. The parents of Case 2 carried APOE ε3/ε2 genotype. Renal biopsy in both cases revealed similar histological findings; diffuse vacuolization of the glomerular basement membranes (GBM) by periodic acid-methenamine silver stain and lipid deposits with a vacuolar lucent appearance in the mesangial matrix and the GBM by electron microscopy (Figure 1E and F). In both cases, half normal LCAT activity was observed by using exogenous substrate, suggesting the diagnosis of FED. However, clinical manifestations with hemolytic anemia and renal involvement coincided with the features of FLD.
Table 1.

Characteristics and lipoprotein profiles of presented casesa

Normal valuesCase 1Case 2Mother of Case 2
SexMaleFemaleFemale
Age (years)273055
c.278 C>T (p.Pro69Leu)Homozygousnonenone
c.950 T>C (p.Met293Thr)noneHeterozygousHeterozygous
Total cholesterol (mg/dL)130–2208473193
Triglycerides (mg/dL)40–150907197
LDL-cholesterol (mg/dL) (direct homogenous assay)70–1392824126
HDL-cholesterol (mg/dL)41–853543
FC (mg/dL)25–60615055
Cholesteryl ester (mg/dL)90–2002323138
FC/TC (%)<2872.668.528.4
RemL-C (mg/dL)0.0–7.534.423.25.4
Phospholipid (mg/dL)150–250157.8178.3ND
Apo A-I (mg/dL)119–1554669124
Apo A-II (mg/dL)25.9–35.75.35.128.3
Apo B (mg/dL)73–1096040113
LCAT activity (nmol/mL/h/37°C)M 67.3–108.231.729.4ND
F 53.3–95.5
APOE genotypeϵ4/ϵ3ϵ2/ϵ2ϵ3/ϵ2

RemL-C, remnant-like particles cholesterol measured with MetaboLead RemL-C; ND, not determined.

Characteristics and lipoprotein profiles of presented casesa RemL-C, remnant-like particles cholesterol measured with MetaboLead RemL-C; ND, not determined.

Plasma lipids and lipoproteins

Both Cases 1 and 2 revealed similar lipid profile; LDL-C and HDL-C were extremely low (Table 1). Furthermore, FC/total cholesterol (TC) ratio was much higher than normal value, suggesting reduced activity of esterification of plasma cholesterol due to LCAT deficiency. In both cases, the lipoproteins in fraction 7–10, corresponding to IDL particle size, were characterized by triglycerides (TG)- and phospholipid (PL)-rich. Since Lp-X is FC- and PL-rich lipoprotein particle, the peaks appeared in fraction 7–10 seem to be remnant lipoproteins containing IDL remnant (Figure 1G and H; arrows). In addition, Lp-X was not detected by agarose gel electrophoresis in both cases. The remnant-like particles cholesterol was measured with MetaboLead RemL-C well-reflects IDL remnant compared with immunoseparation assay, the high values of RemL-C in both cases also support the elevation of IDL remnant.

Discussion

Lynn et al. [6] recently reported that accumulation of Lp-X in renal lesion can stimulate monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-κB. Nishiwaki et al. [7] reported Lp-X is larger than normal LDL-C in size, and the percentages for TG, cholesteryl ester, FC and PL were 9.5, 6.2, 27.6 and 56.8% in Lp-X, respectively. In our cases, we found TG- and PL-rich remnant IDL particles, where TC and FC contents are very low. Previous research has observed that APOE ε2 allele carriers reveal decreased LDL-C and increased TG and lipoprotein remnants, whereas APOE ε4 carriers have increased LDL-C and TG in comparison to ε3/ε3 subjects [8, 9]. It has been suggested that lipoproteins of ε2 carriers have a low affinity for lipoprotein receptors, which induces decreased cholesterol delivery to the hepatocytes and a following upregulation of hepatic sterol synthesis and LDL receptors [10]. Therefore, a decreased conversion of very low-density lipoprotein into LDL and appearance of IDL is observed in ε2 carriers. Baass et al. [5] hypothesized that the presence of the APOE ε2 allele contributed to the accumulation of IDL instead of Lp-X in the patients with LCAT deficiency, but IDL remnant is even higher in Case 1 carrying APOE ε4/ε3 genotype compared with Case 2 with APOE ε2/ε2 genotype (Figure 1G and H). The discrepancy of these observations may attribute to the difference in mutations of LCAT gene rather than APOE genotype and further characterization of enzymatic activities of mutated gene products is required in future investigations. In conclusion, we describe two unrelated FLD patients with corneal opacity, hemolytic anemia, abnormalities in serum lipoprotein profile and lipid accumulation in GBM. Instead of Lp-X, we detected IDL remnant in both cases and similar pathological findings in renal biopsy. Genotyping APOE gene revealed APOE ε4/ε3 in Case 1 and a rare association of APOE ε2/ε2 in Case 2, thus APOE ε2/ε2 may not be the major modifier gene for the appearance of IDL in FLD patients. More cases need to be investigated to draw the definitive conclusions on the relation among LCAT mutation, APOE genotype and lipoprotein profile in FLD patients.
  10 in total

1.  Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice.

Authors:  G Lambert; N Sakai; B L Vaisman; E B Neufeld; B Marteyn; C C Chan; B Paigen; E Lupia; A Thomas; L J Striker; J Blanchette-Mackie; G Csako; J N Brady; R Costello; G E Striker; A T Remaley; H B Brewer; S Santamarina-Fojo
Journal:  J Biol Chem       Date:  2001-02-07       Impact factor: 5.157

Review 2.  Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis.

Authors:  Joerg Heeren; Ulrike Beisiegel; Thomas Grewal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-12-22       Impact factor: 8.311

3.  Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B.

Authors:  E G Lynn; Y L Siow; J Frohlich; G T Cheung; K O
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 4.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.

Authors:  J A Kuivenhoven; H Pritchard; J Hill; J Frohlich; G Assmann; J Kastelein
Journal:  J Lipid Res       Date:  1997-02       Impact factor: 5.922

Review 5.  Apolipoprotein E: far more than a lipid transport protein.

Authors:  R W Mahley; S C Rall
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

6.  Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype.

Authors:  Alexis Baass; Hanny Wassef; Michel Tremblay; Lise Bernier; Robert Dufour; Jean Davignon
Journal:  Atherosclerosis       Date:  2009-05-21       Impact factor: 5.162

7.  Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.

Authors:  H Funke; A von Eckardstein; P H Pritchard; A E Hornby; H Wiebusch; C Motti; M R Hayden; C Dachet; B Jacotot; U Gerdes
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

8.  Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X.

Authors:  Masato Nishiwaki; Katsunori Ikewaki; Giovanni Bader; Hassan Nazih; Minna Hannuksela; Alan T Remaley; Robert D Shamburek; H Bryan Brewer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-16       Impact factor: 8.311

9.  Familial lecithin:cholesterol acyltransferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval.

Authors:  M Guérin; P J Dolphin; M J Chapman
Journal:  Atherosclerosis       Date:  1993-12       Impact factor: 5.162

10.  Gender-related effect of apo E polymorphism on lipoprotein particle sizes in the middle-aged subjects.

Authors:  Aleksandra Topic; Vesna Spasojevic Kalimanovska; Aleksandra Zeljkovic; Jelena Vekic; Zorana Jelic Ivanovic
Journal:  Clin Biochem       Date:  2007-12-04       Impact factor: 3.281

  10 in total
  4 in total

1.  A case of acquired lecithin:cholesterol acyltransferase deficiency with sarcoidosis that remitted spontaneously.

Authors:  Tanino Akiko; Takafumi Okura; Tomoaki Nagao; Masayoshi Kukida; Daijiro Enomoto; Ken-Ichi Miyoshi; Jitsuo Higaki; Masayuki Kuroda; Hideaki Bujo
Journal:  CEN Case Rep       Date:  2016-06-07

Review 2.  Current Status of Familial LCAT Deficiency in Japan.

Authors:  Masayuki Kuroda; Hideaki Bujo; Koutaro Yokote; Takeyoshi Murano; Takashi Yamaguchi; Masatsune Ogura; Katsunori Ikewaki; Masahiro Koseki; Yasuo Takeuchi; Atsuko Nakatsuka; Mika Hori; Kota Matsuki; Takashi Miida; Shinji Yokoyama; Jun Wada; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-04-18       Impact factor: 4.928

Review 3.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

4.  LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred.

Authors:  Roopa Mehta; Daniel Elías-López; Alexandro J Martagón; Oscar A Pérez-Méndez; Maria Luisa Ordóñez Sánchez; Yayoi Segura; Maria Teresa Tusié; Carlos A Aguilar-Salinas
Journal:  Lipids Health Dis       Date:  2021-07-13       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.